Business Continuity Through Infection Control and Telework Amid the Spread of COVID-19
First written in FY2021-Q1. 2 of 3 entries say "Restated". Latest entry: FY2021.
The whole theme swung hardest in 2026: 1 of 12 companies on the "Worse" side.
108 other companies' latest entry also says "Restated".
- FY2021RestatedAnnual report
「As measures against COVID-19, we are continuing to maintain a stable supply of pharmaceuticals and other products by taking various measures under the guidance of infection-control specialists to ensure the safety of customers and employees, including using online meetings with medical institutions and other parties and thoroughly cleaning and disinfecting vehicles and equipment.」
The Company continued infection-control measures including online meetings and the cleaning and disinfection of vehicles and equipment, while maintaining a stable supply of pharmaceuticals and other products. - FY2021-Q2RestatedAnnual report
「As measures against COVID-19, we are continuing to maintain a stable supply of pharmaceuticals and other products by taking various measures under the guidance of infection-control specialists to ensure the safety of customers and employees, including refraining from in-person sales activities at medical institutions and thoroughly cleaning and disinfecting vehicles and equipment.」
Amid the spread of the infection, the Company continued infection-control measures such as refraining from in-person sales activities and cleaning and disinfecting vehicles and equipment, while maintaining a stable supply of pharmaceuticals and other products. - FY2021-Q1First statedAnnual report
「Since the declaration of a state of emergency was issued, we have refrained from in-person sales activities at medical institutions to ensure the safety of customers and employees, while continuing to maintain a stable supply of pharmaceuticals and other products by taking various measures under the guidance of infection-control specialists, including thorough cleaning and disinfection of vehicles and equipment.」
As part of its response to COVID-19, the Company implemented infection-control measures such as refraining from in-person sales activities and cleaning and disinfecting vehicles and equipment, and indicated that it would continue efforts to maintain a stable supply of pharmaceuticals and other products. In the animal-health pharmaceutical business, it also disclosed that it was refraining from visits and taking orders through telework.